
- /
- Supported exchanges
- / F
- / BUW.F
BIO-RAD LABS INC. B DL 1 (BUW F) stock market data APIs
BIO-RAD LABS INC. B DL 1 Financial Data Overview
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get BIO-RAD LABS INC. B DL 1 data using free add-ons & libraries
Get BIO-RAD LABS INC. B DL 1 Fundamental Data
BIO-RAD LABS INC. B DL 1 Fundamental data includes:
- Net Revenue: 2 541 M
- EBITDA: 427 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIO-RAD LABS INC. B DL 1 News

Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference
HERCULES, Calif., May 29, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the ...


Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
HERCULES, Calif., May 12, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its ...

Bio-Rad Laboratories First Quarter 2025 Earnings: EPS: US$2.29 (vs US$13.46 in 1Q 2024)
Bio-Rad Laboratories (NYSE:BIO) First Quarter 2025 Results Key Financial Results Revenue: US$585.4m (down 4.2% from 1Q 2024). Net income: US$64.0m (down 83% from 1Q 2024). Profit margin: 11% (down f...

Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report
Bio-Rad Laboratories, Inc. (NYSE:BIO) shareholders are probably feeling a little disappointed, since its shares fell 2.6% to US$236 in the week after its latest quarterly results. Overall the results ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.